8-K

================================================================================

                             UNITED STATES
                  SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C. 20549


                               FORM 8-K

            CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
                OF THE SECURITIES EXCHANGE ACT OF 1934

                           November 23, 2004
           Date of Report (Date of earliest event reported)


                    COMPETITIVE TECHNOLOGIES, INC.
        (Exact name of registrant as specified in its charter)

            Delaware                  1-8696                 36-2664428
(State or other jurisdiction of     (Commission           (I.R.S. Employer
         incorporation)             File Number )       Identification No.)

            1960 Bronson Road, Fairfield, Connecticut 06824
          (Address of principal executive offices) (Zip Code)

                            (203) 255-6044
         (Registrant's telephone number, including area code)


                            Not Applicable
     (Former Name or Former Address, if Changed Since Last Report)


         Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

================================================================================


Item 8.01 Other Events.

         On November 23, 2004, Competitive Technologies, Inc. ("CTT")
announced that a homocysteine assay license had been granted to
Diagnostics Products Corp. ("DPC") under CTT's U.S. Patent Number
4,940,658 relating to homocysteine medical tests. Pursuant to the
license, DPC will pay CTT a license fee of $1.375 million (which CTT
will share with its client according to the terms of its license
agreement), releasing DPC's customers of any obligation to pay
royalties to CTT for homocysteine test results obtained using DPC
assays in the past, and DPC will pay CTT royalties on sales of DPC
homocysteine assays using DPC's IMMULITE(R) and RIA products.


A copy of the press release is attached as Exhibit 99.1.


Item 9.01.        Financial Statements and Exhibits

         (c)      Exhibits

Exhibit No.                Description
- ------------               --------------------------------------
Exhibit 99.1               Press release dated November 23, 2004.


                              SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.


                                          COMPETITIVE TECHNOLOGIES, INC.
                                          ------------------------------
Date:    November 24, 2004                By: /s/ John B. Nano
                                              Name:  John B. Nano
                                              Title: President and
                                              Chief Executive Officer







                             EXHIBIT INDEX

Exhibit No.                Description

Exhibit 99.1               Press release dated November 23, 2004 announcing
                           that CTT had granted a license to
                           Diagnostics Products Corp.

EX-99.1

                                                          Exhibit 99.1
                       Competitive Technologies
       Licenses Homocysteine Assay to Diagnostic Products Corp.

    Business Editors/Health/Medical Writers

    FAIRFIELD, Conn. & LOS ANGELES--(BUSINESS WIRE)--Nov. 23, 2004--

    DPC Homocysteine Assays Carry Pass-Through License to Customers

    Competitive Technologies, Inc. (AMEX:CTT) and Diagnostics Products
Corp. (NYSE:DP) announced today that a homocysteine assay license has
been granted to DPC under CTT's U.S. Patent Number 4,940,658 relating
to homocysteine medical tests.
    "We are very pleased to issue this license to DPC, a recognized
leader in the field of immunodiagnostics," said Aris D. Despo, CTT's
VP Life Science Business Development. "This agreement marks another
successful step in CTT's active licensing and royalty collection
program for the homocysteine assay. We are proceeding with our
strategy of enforcing the patent rights of CTT and its clients as
affirmed by both the Federal Appeals and Federal District Courts."
    John B. Nano, CTT's President and CEO, said, "The agreement with
DPC is further validation of CTT's homocysteine licensing program. CTT
continues to expand its recurring revenue stream by leveraging
near-term opportunities while executing our long-term strategies for
sustained growth. CTT's first quarter will show strong revenue growth
and profitability, with the DPC royalty payments further strengthening
our second quarter results."
    "This license permits DPC customers to continue to perform
homocysteine assays without concern about possible infringement of the
CTT homocysteine assay patent," stated Michael Ziering, CEO of DPC,
"and it demonstrates our commitment to our customers and their needs."
    Under the agreement, DPC is granted a license under the CTT patent
and will pay royalties on sales of DPC homocysteine assays using DPC's
IMMULITE(R) and RIA products. DPC's homocysteine assay customers,
other than those with unsettled litigation matters, will be covered by
the DPC license from CTT. DPC customers that have separate
homocysteine licenses from CTT will be relieved of their obligation to
pay royalties on reportable homocysteine results obtained using the
DPC assay by virtue of the royalty paid by DPC to CTT.
    The negotiated agreement between CTT and DPC includes an up-front
license fee of $1.375 million, releasing DPC's customers of any
obligation to pay royalties to CTT for homocysteine test results
obtained using DPC assays in the past.
    The settlement and license does not relieve DPC customers for
royalties on past or future assays for methylmalonic acid, for which
CTT will separately require a license to perform such assays.
    The homocysteine patent is derived from discoveries made by CTT's
clients, Drs. Robert Allen and Sally Stabler from the University of
Colorado and the late Dr. John Lindenbaum from Columbia University.

    About Diagnostic Products Corporation

    Diagnostic Products Corporation, founded in 1971, is the global
leader dedicated exclusively to immunodiagnostics. DPC's product menu
includes about 75 immunoassays and over 350 specific allergens and
allergy panels. In addition, DPC addresses the chemistry and
laboratory automation testing needs of its customers through
partnerships with manufacturers of chemistry systems and reagents. The
combined chemistry and immunoassay menu is one of the largest and most
diversified available, covering most laboratory tests requested. DPC
also designs and manufactures automated laboratory instrumentation,
which provides fast, accurate results while reducing labor and reagent
costs. DPC sells its products to hospitals, clinics and laboratories
in more than 100 countries.
    DPC is committed to delivering to customers the highest quality
products with superior service and support. The turquoise zebra icon
symbolizes DPC's uniqueness in the immunodiagnostic industry as "a
company that stands out." Additional Company information can be found
on the Company's website at www.dpcweb.com.

    Except for the historical information contained herein, this press
release contains forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially.
These factors include the effects of governmental and other actions
relating to the FDA's decision that its Application Integrity Policy
should be applied to the Company or relating to the Company's Chinese
affiliate; the rate of customer demand for the Company's products; the
Company's ability to successfully market new and existing products;
its dependence on certain suppliers; domestic and foreign government
regulation; its ability to keep abreast of technological innovations
and to translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC reports
and filings.

    About Competitive Technologies, Inc.

    Competitive Technologies, established in 1968, is a full service
technology transfer and licensing provider focused on the technology
needs of its customers and transforming those requirements into
commercially viable solutions. CTT is a global leader in identifying,
developing and commercializing innovative technologies in life,
digital, nano, and physical sciences developed by universities,
companies and inventors. The global market for technology transfer
services is estimated at $150 billion annually. CTT maximizes the
value of intellectual assets for the benefit of its customers, clients
and shareholders. Visit CTT's website: www.competitivetech.net.

    Statements about our future expectations, including development
and regulatory plans, and all other statements in this document other
than historical facts are "forward-looking statements" within the
meaning of applicable Federal Securities Laws, and are not guarantees
of future performance. These statements involve risks and
uncertainties inherent in our business, including those set forth in
Item 7 under the caption "Risk Factors," in our most recent Annual
Report on Form 10-K filed with the SEC on October 29, 2004, and other
factors that may be described in our other filings with the SEC, and
are subject to change at any time. Our actual results could differ
materially from these forward-looking statements. We undertake no
obligation to update publicly any forward-looking statement.


    CONTACT: Strategic IR, Inc.
             Johnnie D. Johnson, 212-754-6565
                                 212-754-4333 (fax)
             jdjohnson@strategic-ir.com
             or
             ctt@competitivetech.net